Background

Hepatitis C virus (HCV) is the most common chronic bloodborne pathogen in the United States. HCV is primarily acquired by large or repeated percutaneous exposures to blood, with injection drug use being the strongest risk factor. Based on a national survey of households, approximately 1.6 percent of U.S. adults over 20 years of age have antibodies to HCV, indicating prior acute HCV infection. About 78 percent of patients with acute HCV infection develop chronic HCV infection, defined by the presence of persistent viremia.

Chronic HCV infection has a variable course, but it is a leading cause of complications from chronic liver disease, including cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Chronic HCV infection is associated with an estimated 15,000 deaths each year in the United States, and it is the most common indication for liver transplantation among American adults, accounting for more than 30 percent of cases. The prevalence of chronic HCV infection is thought to have peaked in 2001 at 3.6 million people, and the yearly incidence has declined from more than 200,000 cases per year in the 1980s to around 16,000 cases in 2009. However, complications related to chronic HCV infection, which frequently occur only after decades of infection, are expected to rise for another 10 to 13 years.

Effective Health Care Program

The Effective Health Care Program was initiated in 2005 to provide valid evidence about the comparative effectiveness of different medical interventions. The object is to help consumers, health care providers, and others in making informed choices among treatment alternatives. Through its Comparative Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments for high-priority health conditions. It also promotes and generates new scientific evidence by identifying gaps in existing scientific evidence and supporting new research.

The program puts special emphasis on translating findings into a variety of useful formats for different stakeholders, including consumers.

The full report and this summary are available at www.effectivehealthcare.ahrq.gov/reports/final.cfm.
The goal of antiviral treatment for chronic HCV infection is to prevent the long-term health complications associated with HCV infection, such as cirrhosis, hepatic decompensation, and liver cancer, but it is extremely difficult to design and carry out clinical trials long and large enough to provide direct evidence related to these outcomes. The sustained virologic response (SVR) rate, typically defined as the proportion of patients who experience a decline in HCV-RNA (hepatitis C virus ribonucleic acid) to undetectable levels 24 weeks following completion of antiviral treatment, is the standard marker of successful treatment in clinical trials because an SVR is strongly associated with the long-term absence of viremia. Recent studies have evaluated the association between achieving an SVR and reductions in mortality, liver failure, and cancer.

In the early 2000s, the combination of “pegylated” interferon plus ribavirin became the standard antiviral treatment for HCV infection. Pegylation refers to the cross-linking of polyethylene glycol molecules to the interferon molecule, which delays renal clearance and thereby permits less frequent dosing (once weekly vs. three times a week with standard interferon). Dual therapy with pegylated interferon plus ribavirin is associated with higher SVR rates (about 55–60 percent overall) than either standard interferon plus ribavirin or pegylated interferon monotherapy. Currently, two pegylated interferons are available: pegylated interferon alfa-2a and pegylated interferon alfa-2b. Although previous reviews found insufficient evidence to determine whether combination therapy with pegylated interferon alfa-2a or pegylated interferon alfa-2b plus ribavirin is more effective, more head-to-head trials directly comparing these two regimens are now available. A number of factors affect response to antiviral treatment. The two major pretreatment predictors of SVR are the viral genotype and the pretreatment viral load. In the United States, genotype 1 infection is found in around three-quarters of HCV-infected patients. HCV genotype 1 infection is associated with a substantially lower response to antiviral treatment than infection with genotypes 2 and 3, which are present in about 20 percent of HCV-infected patients. A pretreatment viral load of <600,000 international units per milliliter (IU/mL) is associated with higher likelihood of achieving an SVR. Other factors less consistently or less strongly associated with an increased likelihood of achieving an SVR include female sex, age less than 40 years, non-Black race, lower body weight (≤75 kg), absence of insulin resistance, elevated alanine aminotransferase levels, and absence of bridging fibrosis or cirrhosis on liver biopsy. Effects of race on the likelihood of achieving an SVR may be due in part to polymorphisms in the interleukin-28B (IL28B) gene.

An issue complicating antiviral treatment is the high rate of adverse effects observed with interferon-based therapy, including flulike symptoms, fatigue, and neuropsychiatric and hematologic adverse effects. Such adverse effects can be difficult to tolerate and can lead to premature discontinuation of therapy.

In 2011, the U.S. Food and Drug Administration (FDA) approved the first direct acting antiviral agents, boceprevir (trade name Victrelis™) and telaprevir (trade name Incivek®), for treatment of chronic HCV genotype 1 infection. Both drugs are classified as nonstructural 3/4A protease inhibitors, with a potential advantage of shorter duration of therapy (24 to 28 weeks) compared with standard dual therapy with pegylated interferon (alfa-2a or 2b) plus ribavirin for genotype 1 infection (48 weeks). Either drug is administered in combination with pegylated interferon (alfa-2a or 2b) plus ribavirin. Understanding the comparative benefits and harms of the various antiviral regimens is critical for making informed treatment decisions in patients with chronic HCV infection, particularly given the availability of new treatment options. This review assesses the comparative effectiveness of antiviral treatments in adults with chronic HCV infection who have not received previous antiviral drug treatment. In addition to assessing the comparative effectiveness of different drug regimens, the review evaluates the effects of different medication doses, durations of therapy, and dosing strategies (such as weight-based or response-guided vs. fixed treatment). To help with individualized clinical decisionmaking regarding antiviral therapy for chronic HCV infection, the review also evaluates how comparative effectiveness varies depending on HCV genotype, viral load, and other demographic and clinical characteristics. Given the need to understand the effects of treatment in people with HCV infection identified by screening in order to assess the potential benefits and harms of screening, this review will be used, together with a separate review on HCV screening, by the U.S. Preventive Services Task Force to update its HCV screening recommendations.
Objectives

The following Key Questions are the focus of our report:

Key Question 1

a. What is the comparative effectiveness of antiviral treatment in improving health outcomes in patients with HCV infection?

b. How does the comparative effectiveness of antiviral treatment for health outcomes vary according to patient subgroup characteristics, including but not limited to HCV genotype, age, race, sex, stage of disease, or genetic markers?

Key Question 2

a. What is the comparative effectiveness of antiviral treatments on intermediate outcomes, such as the rate of SVR or histologic changes in the liver?

b. How does the comparative effectiveness of antiviral treatment for intermediate outcomes vary according to patient subgroup characteristics, including but not limited to HCV genotype, age, race, sex, stage of disease, or genetic markers?

Key Question 3

a. What are the comparative harms associated with antiviral treatments?

b. Do these harms differ according to patient subgroup characteristics, including HCV genotype, age, race, sex, stage of disease, or genetic markers?

Key Question 4

Have improvements in intermediate outcomes (SVR, histologic changes) been shown to reduce the risk or rates of adverse health outcomes from HCV infection?

Analytic Framework

The analytic framework that guided this report is shown in Figure A. The numbers in the analytic framework indicate the Key Questions listed above. The population was patients with chronic HCV infection who were receiving antiviral therapy. The interventions were dual therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirin, or triple therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirin plus a protease inhibitor approved by the FDA (either boceprevir or telaprevir). Comparisons were between different regimens, as well as between regimens including the same drugs administered at different doses or for different durations. Intermediate outcomes were sustained virologic response and hepatic histological improvement. Final outcomes were morbidity and mortality from HCV infection (including hepatic cirrhosis, HCC, and liver transplantation rates) and quality of life, as well as harms of antiviral therapies (including flulike symptoms).
symptoms, hematologic effects, rash, and psychiatric effects).

Methods

Input From Stakeholders

The topic of treatment for HCV infection was nominated for a comparative effectiveness review (CER) in a public process. The Key Questions were proposed in the public nomination process and developed by investigators from the Evidence-based Practice Center (EPC) with contributions from expert Key Informants (KI), who helped refine Key Questions, identify important methodological and clinical issues, and define parameters for the review of evidence. The revised Key Questions were then posted to a public Web site for comment. The Agency for Healthcare Research and Quality (AHRQ) and the EPC agreed on the final Key Questions after reviewing the public comments and receiving additional advice from a Technical Expert Panel (TEP) convened for this report. We then drafted a protocol for this CER, which the TEP reviewed. Access it from the AHRQ Web site, where it was posted in November 2011: (www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pag eaction=displayproduct&productid=855).

A multidisciplinary group of clinicians, researchers, and patient advocates with expertise in hepatitis C treatment and research were selected to serve as the TEP members to provide high-level content and methodological expertise throughout the development of the review. Prior to participation in this report, the TEP members disclosed all financial or other conflicts of interest. The AHRQ Task Order Officer and the authors reviewed all of these disclosures and determined the panel members had no significant conflicts of interest that precluded participation. KIs and TEP members had expertise in hepatology, epidemiology, screening, and primary care. TEP members and other experts were invited to provide external peer review of the draft report.

Search Strategy and Study Selection

To identify articles relevant to each Key Question, a research librarian searched the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, and Ovid MEDLINE® from 1947 to April 2011 (see Appendix A in the full report for the search strategies), and a final updated search was conducted in August 2012. The search strategies were peer reviewed by another research librarian and revised prior to finalization. Unpublished trials were sought by searching clinical trial registries (ClinicalTrials.gov, Current Controlled Trials, Clinical Trial Results, WHO Trial Registries) and grants databases (NIHRePORTER, HSRProj, and AHRQ GOLD). Scientific Information Packets on unpublished and published trials were solicited from manufacturers of included antiviral drugs through the Scientific Resource Center. We also hand-searched the reference lists of relevant studies. Searches were updated before the report was finalized to identify relevant new publications.

Studies were selected according to criteria developed for inclusion and exclusion. The selection criteria were based on the Key Questions and the populations, interventions, comparators, outcomes, timing, and setting (PICOTS) approach. Papers were selected for full review if they were about chronic HCV infection, were relevant to Key Questions in the analytic framework, and met the predefined inclusion criteria. To evaluate the potential effects of publication bias, we included trials published only as conference abstracts of sensitivity analyses. We restricted inclusion to English language articles. Studies of nonhuman subjects were also excluded, and studies had to include original data.

Abstracts and full-text articles were dual reviewed for inclusion and exclusion for each Key Question. Full-text articles were obtained for all studies identified as potentially meeting inclusion criteria. Two investigators independently reviewed all full-text articles for final inclusion or exclusion, and discrepancies were resolved through discussion and consensus, with a third investigator making the final decision if necessary.

Data Extraction and Quality Assessment

We assessed the quality of each study based on predefined criteria (Appendix E in the full report). We adapted criteria from methods proposed by Downs and Black (observational studies), the USPSTF, and the Quality Assessment of Diagnostic Accuracy Studies-2 Group. The criteria used are consistent with the approach recommended by AHRQ in the Methods Guide for Effectiveness and Comparative Effectiveness Reviews (Methods Guide). We used the term “quality” rather than the alternate term “risk of bias.” Although both refer to internal validity, “quality” may be more familiar to most users and has potential advantages in terms of readability.

We rated the quality of each randomized trial based on the methods used for randomization, allocation concealment, and blinding; the similarity of compared groups at baseline; maintenance of comparable groups; adequate reporting of dropouts, attrition, crossover, adherence, and
Data Synthesis and Rating the Strength of the Body of Evidence

We performed meta-analysis of trials that evaluated similar populations, interventions, comparisons, and outcomes to estimate pooled relative risks.\textsuperscript{35} When present, statistical heterogeneity was explored through subgroup and sensitivity analyses, as well as qualitatively. Subgroup analyses were performed in groups stratified by HCV genotype as well as by race, age, body weight, viral load, stage/severity of disease, and IL-28b status when these data were available. We performed sensitivity analysis by excluding poor-quality studies and outlier trials, and by including results from studies published only as abstracts to evaluate the stability of estimates and conclusions. We did not perform meta-analyses for Key Question 4 because all studies were observational and had important methodologic shortcomings. These studies were synthesized qualitatively.

We rated the strength of evidence for each Key Question using the four categories recommended in the AHRQ Methods Guide.\textsuperscript{33} We synthesized the overall quality of each body of evidence based on the type and quality of studies (graded good, fair, or poor); the precision of the estimate of effect based on the number and size of studies and confidence intervals for the estimates (graded good, fair, or poor); the consistency of results between studies (graded high, moderate, or low); the directness of the evidence linking the intervention and health outcomes (graded direct or indirect). We did not downgrade a body of evidence for directness that evaluated an intermediate outcome if the intermediate outcome was the specific focus of the Key Question. We were not able to formally assess for publication bias due to small numbers of studies, methodological shortcomings, or differences across studies in designs, measured outcomes, and other factors.

We graded the strength of evidence for each comparison and outcome by using the four categories recommended in the AHRQ Methods Guide: A “high” grade indicates high confidence that the evidence reflects the true effect and that further research is very unlikely to change our confidence in the estimate of effect and will not change the estimate. A “moderate” grade indicates moderate confidence that the evidence reflects the true effect and that further research may change our confidence in the estimate of effect and may change the estimate. A “low” grade indicates low

Contamination; loss to followup; the use of intent-to-treat analysis; and ascertainment of outcomes.\textsuperscript{31}

We rated the quality of each cohort study based on whether it used nonbiased selection methods to create an inception cohort; whether it evaluated comparable groups; whether rates of loss to followup were reported and acceptable; whether it used accurate methods for ascertaining exposures, potential confounders, and outcomes; and whether it performed appropriate statistical analyses of potential confounders.\textsuperscript{31}

Following assessment of individual quality criteria, individual studies were rated good, fair, or poor quality, as defined below.\textsuperscript{33}

Good-quality studies are considered likely to be valid. Good-quality studies clearly describe the population, setting, interventions, and comparison groups; use a valid method for allocation of patients to interventions; clearly report dropouts and have low dropout rates; use appropriate methods for preventing bias; and appropriately measure outcomes and fully report results.

Fair-quality studies have some methodological deficiencies but no flaw or combination of flaws judged likely to cause major bias. The study may be missing information, making it difficult to assess its methods or assess limitations and potential problems. The fair-quality category is broad, and studies with this rating vary in their strengths and weaknesses—the results of some fair-quality studies are likely to be valid, while others are only probably valid.

Poor-quality studies have significant flaws that may invalidate the results. They have a serious or fatal flaw in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting. The results of these studies are judged to be at least as likely to reflect flaws in the study design as true effects of the interventions under investigation. We did not exclude studies rated poor quality a priori, but they were considered to be the least reliable studies when synthesizing the evidence, particularly when discrepancies between studies were present.

We recorded factors important for understanding the applicability of studies, such as whether the publication adequately described the study population, how similar patients were to populations likely to be targeted by screening, whether differences in outcomes were clinically (as well as statistically) significant, and whether the interventions and tests evaluated were reasonably representative of standard practice.\textsuperscript{34} We also recorded the funding source and role of the sponsor. We did not assign a rating of applicability (such as high or low) because applicability may differ based on the user of this report.
confidence that the evidence reflects the true effect and that further research is likely to change the confidence in the estimate of effect and is likely to change the estimate. An “insufficient” grade indicates evidence either is unavailable or is too limited to permit any conclusion.

**Results**

The search and selection of articles are summarized in the study flow diagram (Figure B). Of the 1,096 citations identified at the title and abstract level in the original search, 215 articles met inclusion criteria and were selected for further review of the full text. From updated searches and peer reviewer-suggested citations, an additional 2,352 citations were identified, and 164 of these met inclusion criteria and were selected for full-text review. Of the 379 articles reviewed at the full-text level, a total of 90 studies met inclusion criteria.

No study evaluated comparative effectiveness of current antiviral regimens on long-term clinical outcomes such as mortality, complications of chronic HCV infection, or quality of life.

**Dual Therapy Regimens With Pegylated Interferon Plus Ribavirin**

In trials of treatment-naïve patients, dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a slightly lower likelihood of achieving an SVR than dual therapy with pegylated interferon alfa-2a plus ribavirin, with a difference in absolute SVR rates of about 8 percentage points.\(^{16-19,36-38}\) In patients with genotype 2 or 3 infection, dual therapy for 12 to 16 weeks appears to be associated with a lower likelihood of SVR, compared with dual therapy for 24 weeks, with no differences between 24 weeks and longer courses of therapy.\(^{39-44}\) In trials comparing different doses of dual therapy with pegylated interferon plus ribavirin, lower doses of pegylated interferon alfa-2b were less effective than standard doses,\(^{41,45-49}\) and limited evidence found no clear differential effects of ribavirin dosing.\(^{39,50}\)

There were no clear differences in estimates of relative effectiveness between dual therapy with pegylated interferon alfa-2a plus ribavirin versus dual therapy with pegylated interferon alfa-2b plus ribavirin in patient subgroups defined by demographic or clinical characteristics, although absolute response rates were lower in older patients, Black patients, patients with high viral load, patients with more advanced fibrosis or cirrhosis, and patients with genotype 1 infection.\(^{16,17,19,51}\)

Differences in harms between dual therapy with pegylated interferon alfa-2a plus ribavirin versus pegylated interferon alfa-2b plus ribavirin were relatively small, with no differences in withdrawals due to adverse events, although dual therapy with pegylated interferon alfa-2b was associated with a lower risk of serious adverse events.\(^{16-19,38,52}\)

**Triple Therapy Regimens With Pegylated Interferon, Ribavirin, and Either Boceprevir or Telaprevir**

Trials of antiviral regimens including either boceprevir or telaprevir have been primarily conducted in patients with genotype 1 infection. Triple antiviral regimens (pegylated interferon alfa-2a or alfa-2b, ribavirin, and boceprevir or telaprevir) were associated with a substantially increased likelihood of achieving an SVR than dual therapy with pegylated interferon alfa-2a or alfa-2b plus ribavirin).\(^{26-28,53-57}\)

Two trials found triple therapy with boceprevir for 48 weeks (dual therapy with pegylated interferon alfa-2b plus ribavirin for 4 weeks followed by 44 weeks of triple therapy with the addition of boceprevir) was associated with a higher likelihood of SVR than dual therapy with pegylated interferon alfa-2b plus ribavirin for 48 weeks (pooled relative risk [RR] 1.81, 95% confidence interval [CI] 1.58 to 2.06; \(I^2=0.0\)%), with an absolute increase in SVR rate of 31 percentage points (95% CI 23 to 39).\(^{26,28}\)

Three trials found triple therapy with telaprevir for 24 weeks (pegylated interferon alfa-2a, ribavirin, and telaprevir triple therapy for 12 weeks followed by 12 weeks of pegylated interferon alfa-2a plus ribavirin without telaprevir) was associated with a higher likelihood of SVR than dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks (pooled RR 1.48, 95% CI 1.26 to 1.75; \(I^2=0.0\)%), with an absolute increase in SVR rate of 22 percentage points (95% CI 13 to 31).\(^{27,53,55}\) One trial found response-guided telaprevir triple therapy (8 or 12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 12 or 36 weeks of response-guided dual therapy with pegylated interferon alfa-2a plus ribavirin) was associated with a higher likelihood of SVR than dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks (RR 1.6, 95% CI 1.4 to 1.9), with an absolute increase in SVR rate of 25–31 percentage points.\(^{54}\)

Relative estimates of the effects of triple therapy with either boceprevir or telaprevir, compared with dual
Figure B. Study flow diagram: Treatment for hepatitis C virus infection in adults

Original Search (04/2011): Abstracts of potentially relevant articles reviewed: 1,096
(Identified through bibliographical databases)

Updated Search (04/2012): Abstracts of potentially relevant articles reviewed: 1,699
(Identified through bibliographical databases)

Updated Search (08/2012): Abstracts of potentially relevant articles reviewed: 653
(Identified through bibliographical databases)

Hand searches: 8 Studies included
Hand searches: 14 Studies included

215 Full-text articles reviewed for relevance to Key Questions:
63 Studies Included

36 Full-text articles reviewed for relevance to Key Questions:
5 Studies Included

128 Full-text articles reviewed for relevance to Key Questions:
0 Studies Included

Excluded abstracts/duplicates: 881
Excluded full-text articles: 152
• Wrong outcomes: 7
• Wrong drug/treatment: 2
• Wrong population: 8
• Wrong study design: 7
• Not relevant: 128

Excluded abstracts/duplicates: 1,663
Excluded full-text articles: 31
• Wrong design: 28
• Not relevant: 3

Excluded abstracts/duplicates: 525
Excluded full-text articles: 128
• Used as background: 113
• No original data: 1
• Wrong outcomes: 2
• Wrong population: 3
• Wrong study design: 9

Includes: 90 Studies
(Due to their applicability to more than one Key Question, the total combined number of articles cited for all Key Questions shown below may exceed the number of references indicated in the “Includes” box.)

Key Questions 1 and 1a
1a. 5 studies
1b. 0 studies

Key Questions 2 and 2a
2a. 38 studies
2b. 13 studies

Key Questions 3 and 3a
3a. 13 studies
3b. 3 studies

Key Question 4
4. 28 studies
therapy, were similar across subgroups, except in patients with low viral load, in whom triple therapy was no more effective than dual therapy in achieving an SVR. Triple therapy with boceprevir was associated with increased risk of hematological adverse events and triple therapy with telaprevir with increased risk of anemia and rash (including severe rash) than dual therapy; adverse events were generally self-limited with discontinuation of therapy.\textsuperscript{26,28} All antiviral regimens were associated with a high incidence of flu-like symptoms, with small or no clear differences in risk.

**Sustained Virologic Response After Antiviral Therapy and Clinical Outcomes**

A large cohort study that was well controlled for confounders found that patients with an SVR after antiviral therapy had a lower risk of all-cause mortality than patients with no SVR (adjusted hazard ratio estimates 0.51 to 0.71).\textsuperscript{8} Eighteen other cohort studies also found SVR associated with reduced risk of all-cause mortality, liver-related mortality, and other hepatic complications rather than no SVR, but had more methodological shortcomings.\textsuperscript{9,58-74} Ten of the studies were conducted in Asian countries and might not be directly applicable to U.S. populations.

**Discussion**

**Key Findings and Strength of Evidence**

The evidence reviewed in this study is summarized in Table A. The specific domain scores used to determine the overall strength of evidence for each body of evidence are shown in Appendix G in the full report. We identified no studies that evaluated comparative effectiveness of current antiviral regimens on long-term clinical outcomes such as mortality, complications of chronic HCV infection, or quality of life. Such trials would be difficult to design and carry out due to the long time required for complications of chronic HCV infection to develop in most patients.

**Dual Therapy Regimens With Pegylated Interferon and Ribavirin**

In lieu of direct evidence on long-term clinical outcomes, SVR rates are the primary outcome to assess comparative benefits of different antiviral regimens. In trials of treatment-naïve patients, the likelihood of achieving an SVR was slightly lower with dual therapy with pegylated interferon alfa-2b plus ribavirin compared with dual therapy with pegylated interferon alfa-2a plus ribavirin (pooled RR 0.87, 95% CI 0.80 to 0.95; I^2=27.4%), with a difference in absolute SVR rates of about 8 percentage points. Although the largest study, the Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated Interferon Therapy (IDEAL) trial, found no difference in SVR rates for dual therapy with pegylated interferon alfa-2a plus ribavirin compared with dual therapy with pegylated interferon alfa-2b plus ribavirin, excluding the IDEAL trial from pooled analyses, resulted in similar effect estimates.\textsuperscript{18} Although there was no difference between types of dual therapy regimens in risk of withdrawals due to adverse events, dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a lower risk of serious adverse events than dual therapy with pegylated interferon alfa-2a plus ribavirin (pooled RR 0.76, 95% CI 0.71 to 0.88; I^2=0.0%), suggesting a potential tradeoff between greater benefits and greater harms. However, serious adverse events were only reported in two trials,\textsuperscript{18,19} and the rate of serious adverse events was relatively low (about 4 percent overall in IDEAL), with an absolute difference of about 1 percent, and adverse events with antiviral treatments generally resolve following discontinuation of therapy. Trials found no clear difference in estimates of relative effectiveness of dual therapy with pegylated interferon alfa-2a plus ribavirin compared with dual therapy with pegylated interferon alfa-2b plus ribavirin in patient subgroups stratified by age, sex, race, viral load, fibrosis stage, and genotype, although absolute response rates were lower in older patients, Black patients, patients with high viral load, patients with more advanced fibrosis or cirrhosis, and patients with genotype 1 infection.\textsuperscript{6-19,51} SVR rates ranged from 24 to 42 percent lower in patients with genotype 1 infection compared with patients with genotype 2 or 3.

In patients with genotype 2 or 3 infection, dual therapy for 12 to 16 weeks appears to be associated with a lower likelihood of SVR compared with dual therapy for 24 weeks, with no differences between 24 weeks and longer courses of therapy.\textsuperscript{39-44} Standard doses of pegylated interferon alfa-2b were more effective than lower doses (no trials compared different doses of pegylated interferon alfa-2a).\textsuperscript{41,45-49} Although trials comparing different ribavirin doses found no clear differences, they evaluated different dose comparisons, precluding firm conclusions.\textsuperscript{39,50,75,76}

**Triple Therapy Regimens With Pegylated Interferon, Ribavirin, and Either Boceprevir or Telaprevir**

Trials of triple therapy regimens with the protease inhibitors boceprevir or telaprevir (both approved by the FDA in 2011) in treatment-naïve patients with genotype
1 infection found each associated with substantially higher SVR rates than standard dual therapy without a protease inhibitor. SVR rates with triple therapy were similar to the 70–80 percent observed with dual therapy in patients with genotype 2 or 3 infection.\textsuperscript{23,26,28,33,57,77} Trials that evaluated the telaprevir regimen recommended by the FDA (12 weeks of triple therapy with telaprevir followed by response-guided duration of 12 or 36 weeks of dual therapy) reported SVR rates of 75–80 percent.\textsuperscript{34,56} Trials that evaluated the boceprevir regimen recommended by the FDA for antiviral-naïve patients with cirrhosis (4 weeks of dual therapy lead-in followed by 44 weeks of triple therapy with boceprevir) reported SVR rates of 66–75 percent.\textsuperscript{26,28} Trials that evaluated other regimens in antiviral naïve patients, including fixed duration telaprevir regimens, shorter fixed duration triple therapy boceprevir therapy, and boceprevir without dual therapy lead-in, reported similar or lower SVR rates.

As with the head-to-head trials of dual therapy with pegylated interferon alfa-2a plus ribavirin compared with pegylated interferon alfa-2b plus ribavirin, RR estimates for triple, compared with dual, therapy were similar (or there were no clear differences) in patient subgroups based on age, sex, or race, although absolute SVR rates were lower in older patients and Black patients. In two trials, triple therapy with boceprevir was no more effective than dual therapy in the subgroup of patients with lower HCV-RNA viral load (<600,000 or <800,000 IU/mL),\textsuperscript{26,28} but two trials of triple therapy with telaprevir were inconsistent in showing differential effects depending on baseline viral load.\textsuperscript{54,55} There was insufficient evidence to evaluate relative effectiveness of triple, compared with dual, therapy based on fibrosis stage.

In addition to a higher likelihood of SVR, another advantage of triple therapy regimens in patients with genotype 1 infection is the potential for a shorter duration of treatment (24 or 28 weeks in patients with early virologic response, compared with the standard 48 weeks of dual therapy with pegylated interferon plus ribavirin). Shorter courses of treatment would probably be appealing to patients, given the frequency of bothersome flulike symptoms associated with interferon-based therapy. On the other hand, triple therapy regimens were associated with increased risk of certain harms, in particular hematological adverse events (neutropenia, anemia, and thrombocytopenia) with boceprevir, and anemia and rash (including severe rash in up to about 10 percent of patients, which could result in treatment discontinuation) with telaprevir. However, there was no clear increase in risk of serious adverse events or overall withdrawal due to adverse events with use of protease inhibitors, and the adverse events appear to be self-limited following drug discontinuation.

### Sustained Virologic Response After Antiviral Therapy, and Clinical Outcomes

The strongest evidence on the association between an SVR after antiviral therapy and improved clinical outcomes is a large U.S. Department of Veterans Affairs (VA) cohort study (n=16,864) that adjusted for many confounders and found decreased risk of all-cause mortality compared with no SVR across patient groups stratified by genotype (adjusted hazard ratio [HR] 0.71 [0.60–0.86], 0.62 [0.44–0.87] and 0.51 [0.35–0.75] for genotypes 1, 2, and 3, respectively).\textsuperscript{8} Despite controlling for important confounders, the possibility of residual confounding is suggested by the very rapid separation of mortality curves for people with an SVR versus those without an SVR, which was observed at 3 months after assessment for SVR. This is more rapid than expected given the typically prolonged natural history of HCV infection. Therefore, estimates of effects of SVR on clinical outcomes from this study may be exaggerated, although it is not possible to determine to what degree. Eighteen other cohort studies also found an SVR after antiviral therapy associated with decreased risk of all-cause mortality and complications of chronic HCV infection, including studies specifically of patients with baseline cirrhosis, but had more methodological shortcomings. In addition, 10 of the 19 studies were conducted in Asia, where the incidence of HCC in patients with chronic HCV infection is higher than in the United States,\textsuperscript{78} potentially limiting their generalizability. Other studies found an SVR after antiviral therapy associated with better scores on measures of quality of life than with no SVR, but those studies focused on short-term outcomes and typically did not adjust for confounders or blind patients to SVR status when assessing outcomes.

### Findings in Relationship to What is Already Known

Our findings regarding the comparative effectiveness of dual therapy with pegylated interferon alfa-2b plus ribavirin compared with dual therapy with pegylated interferon alfa-2a plus ribavirin are consistent with recent systematic reviews that also found the former associated with a lower likelihood of SVR.\textsuperscript{14,79} Our findings of no clear difference in comparative effectiveness between 12 to 16 weeks compared with 24 weeks of response-guided dual therapy with pegylated interferon plus ribavirin in hepatitis C genotype 2 or 3 infection with rapid virologic response are discordant with a recent
**Table A. Summary of evidence on comparative effectiveness of treatment for hepatitis C**

<table>
<thead>
<tr>
<th>Key Question</th>
<th>Outcome</th>
<th>Summary of Evidence</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key Question 1a</strong>&lt;br&gt;What is the comparative effectiveness of antiviral treatment in improving health outcomes in patients with HCV infection?</td>
<td>Long-term clinical outcomes</td>
<td>No evidence.</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td>Short-term mortality</td>
<td>Three trials that compared current antiviral regimens found no differences in risk of short-term mortality, but reported very few (20 total) events.</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Short-term quality of life</td>
<td>One open-label randomized trial of patients with genotype 4 infection found dual therapy with pegylated interferon alfa-2a plus ribavirin associated with statistically significant, slightly better short-term scores on some quality of life assessments compared with dual therapy with pegylated interferon alfa-2b plus ribavirin.</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Key Question 1b</strong>&lt;br&gt;How does the comparative effectiveness of antiviral treatment for health outcomes vary according to patient subgroup characteristics?</td>
<td>Any clinical outcome</td>
<td>No evidence.</td>
<td>Insufficient</td>
</tr>
<tr>
<td><strong>Key Question 2a</strong>&lt;br&gt;What is the comparative effectiveness of antiviral treatments on intermediate outcomes?</td>
<td>Dual Therapy With Pegylated Interferon Alfa-2b Plus Ribavirin vs. Dual Therapy With Pegylated Interferon Alfa-2a Plus Ribavirin</td>
<td>Seven trials found dual therapy with standard doses of pegylated interferon alfa-2b plus ribavirin associated with lower likelihood of achieving an SVR than pegylated interferon alfa-2a plus ribavirin (pooled RR 0.87, 95% CI 0.80 to 0.95; I²=27.4%), with an absolute difference in SVR rates of 8 percentage points (95% CI 3 to 14).</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin: Duration Effects</td>
<td>Two trials of patients with genotype 2 or 3 infection found no difference in likelihood of achieving an SVR between 48 vs. 24 weeks of dual therapy with pegylated interferon alfa-2a plus ribavirin (pooled RR 0.97, 95% CI 0.84 to 1.1; I²=43%).</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Four trials of patients with genotype 2 or 3 infection found 24 weeks of dual therapy with pegylated interferon (alfa-2a or alfa-2b) more effective than 12-16 weeks for achieving an SVR (pooled RR 1.15, 95% CI 1.02 to 1.29; I²=79.5%). Relative risk estimates ranged from 1.01 to 1.33 in the four trials and may have varied in part due to differences across studies in ribavirin dosing.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Three trials of patients with genotype 2 or 3 infection with a rapid virologic response (undetectable HCV-RNA by week 4) found no differences between 24 vs. 12-16 weeks of dual therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirin (pooled RR 0.99, 95% CI 0.86 to 1.14; I²=66.7%). Relative risk estimates ranged from 0.89 to 1.2.</td>
<td>Moderate</td>
</tr>
<tr>
<td>Key Question 2a</td>
<td>Outcome</td>
<td>Summary of Evidence</td>
<td>Strength of Evidence</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td><strong>Key Question</strong></td>
<td><strong>Outcome</strong></td>
<td><strong>Summary of Evidence</strong></td>
<td><strong>Strength of Evidence</strong></td>
</tr>
<tr>
<td><strong>What is the comparative effectiveness of antiviral treatments on intermediate outcomes?</strong> (continued)</td>
<td><strong>Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin: Dose Effects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained virologic response</td>
<td>Six trials of patients with genotype 2 or 3 infection found lower doses of pegylated interferon alfa-2b (0.75-1.0 mcg/kg or 50 mcg) associated with lower likelihood of achieving an SVR than higher doses (1.5 mcg/kg or 100-150 mcg) (pooled RR 0.90; 95% CI 0.81 to 0.99; I^2=20.2%).</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Sustained virologic response</td>
<td>Three trials of patients with genotype 2 or 3 infection who did not specifically have advanced fibrosis or cirrhosis found no clear difference in likelihood of SVR between lower doses of ribavirin (400 or 800 mg flat dose or 600 to 800 mg weight-based dose) vs. higher doses (800 or 1,200 mg flat dose or 800 to 1,400 mg weight-based dose).</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Sustained virologic response</td>
<td>One small trial of patients with genotype 2 or 3 infection (n=60) and advanced fibrosis or cirrhosis (Ishak stage 4-6) found 600 to 800 mg daily of ribavirin associated with lower likelihood of SVR than 1,000 to 1,200 mg daily (45 vs. 72%, RR 0.62, 95% CI 0.40 to 0.98).</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2b, Ribavirin, and Boceprevir vs. Dual Therapy With Pegylated Interferon Alfa-2b Plus Ribavirin</strong></td>
<td>Sustained virologic response</td>
<td>Two trials of patients with genotype 1 infection found triple therapy with boceprevir (pegylated interferon alfa-2b plus ribavirin for 4 weeks, followed by the addition of boceprevir for 44 weeks) associated with higher likelihood of SVR than dual therapy with pegylated interferon alfa-2b plus ribavirin therapy for 48 weeks (pooled RR 1.81; 95% CI 1.58 to 2.06; I^2=0.0%), with an absolute increase in SVR rate of 31% (95% CI 23 to 39).</td>
<td>Moderate</td>
</tr>
<tr>
<td>Sustained virologic response</td>
<td>One trial of patients with genotype 1 infection found 48 weeks of triple therapy with boceprevir using a low dose of ribavirin (400-1,000 mg daily) associated with a non–statistically significant trend toward lower likelihood of SVR compared with 48 weeks of triple therapy with a standard ribavirin dose (800-1,400 mg daily) (36% vs. 50%, RR 0.71, 95% CI 0.39 to 1.3).</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2a or Alfa-2b, Ribavirin, and Telaprevir vs. Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin</strong></td>
<td>Sustained virologic response</td>
<td>Three trials of patients with genotype 1 infection found triple therapy with telaprevir for 24 weeks (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 12 weeks of pegylated interferon alfa-2a plus ribavirin) associated with a higher likelihood of SVR than dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks (pooled RR 1.48, 95% CI 1.26 to 1.75; I^2=0.0%), with an absolute increase in SVR rate of 22% (95% CI 13 to 31).</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
### Table A. Summary of evidence on comparative effectiveness of treatment for hepatitis C (continued)

<table>
<thead>
<tr>
<th>Key Question</th>
<th>Outcome</th>
<th>Summary of Evidence</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key Question 2a</strong>&lt;br&gt;What is the comparative effectiveness of antiviral treatments on intermediate outcomes? (continued)</td>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2a or Alfa-2b, Ribavirin, and Telaprevir vs. Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin (continued)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>One trial of patients with genotype 1 infection found no difference in likelihood of SVR between triple therapy with pegylated interferon, ribavirin, and telaprevir for 12 weeks vs. dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>One trial of patients with genotype 1 infection found response-guided triple therapy with telaprevir (pegylated interferon alfa-2a, ribavirin, and telaprevir for 8 or 12 weeks followed by a response-guided dual therapy with pegylated interferon alfa-2a plus ribavirin for an additional 12 or 36 weeks) associated with a higher likelihood of SVR than dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks (RR 1.6, 95% CI 1.4 to 1.9), with an absolute increase in SVR rate ranging from 25% to 31%. The regimen with 8 weeks of telaprevir was associated with a slightly lower SVR rate than the 12 week telaprevir regimen (69% vs. 75%).</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>One trial of patients with genotype 1 infection found no difference in likelihood of SVR between triple therapy with telaprevir for 48 weeks (12 weeks of triple therapy with pegylated interferon alfa-2a, ribavirin, and telaprevir followed by 36 weeks of dual therapy with pegylated interferon alfa-2a plus ribavirin) vs. triple therapy with telaprevir for 24 weeks (12 weeks of triple therapy followed by 12 weeks of dual therapy).</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2a, Ribavirin, and Telaprevir: Dose Effects of Pegylated Interferon Alfa-2a vs. Alfa-2b and Duration Effects</strong></td>
<td>Sustained virologic response</td>
<td>One trial of response-guided triple therapy with telaprevir (24 or 48 weeks, based on absence or presence of HCV-RNA from weeks 4 through 20) found similar SVR rates (81–85%) for regimens that varied on telaprevir dose (750 mg tid vs. 1,125 mg bid) and type of pegylated interferon (alfa-2a or alfa-2b).</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>One trial of patients with an extended rapid virologic response to initial triple therapy with telaprevir reported similar, high (92% and 88%) SVR rates in patients randomized to a total of 24 or 48 weeks of therapy.</td>
<td>Low</td>
</tr>
<tr>
<td>Key Question</td>
<td>Outcome</td>
<td>Summary of Evidence</td>
<td>Strength of Evidence</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td><strong>Key Question 2b</strong> How does the comparative effectiveness of antiviral treatment for intermediate outcomes vary according to patient subgroup characteristics?</td>
<td>Sustained virologic response</td>
<td>Dual Therapy With Pegylated Interferon Alfa-2b Plus Ribavirin vs. Dual Therapy With Pegylated Interferon Alfa-2a Plus Ribavirin</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The largest randomized trial (n=3,070) of dual therapy with pegylated interferon alfa-2a plus ribavirin vs. dual therapy with pegylated interferon alfa-2b plus ribavirin found no clear differences in relative risk estimates for SVR in genotype 1 patients stratified by race, sex, age, baseline fibrosis stage, or baseline viral load. Characteristics associated with lower absolute SVR rates across dual therapy regimens were older age, Black race, advanced fibrosis or cirrhosis, and high baseline viral load.</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Four randomized trials of dual therapy with pegylated interferon alfa-2a plus ribavirin vs. dual therapy with pegylated interferon alfa-2b plus ribavirin found no clear differences in relative risk estimates for SVR in patients stratified by genotype. Genotype 1 infection was associated with a lower absolute SVR rate than genotypes 2 or 3.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Two trials of triple therapy with boceprevir for 48 weeks (4 weeks of dual therapy lead-in with pegylated interferon plus ribavirin followed by 44 weeks of triple therapy with pegylated interferon, ribavirin, and boceprevir) found no difference in relative risk estimates for SVR in men vs. women, and no clear difference in relative risk estimates for Black vs. non-Black patients. Black race was associated with a lower absolute SVR rate than non-Black race.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Two trials found triple therapy with pegylated interferon alfa-2b, ribavirin, and boceprevir associated with higher likelihood of achieving SVR than dual therapy with pegylated interferon alfa-2b plus ribavirin in patients with high baseline HCV-RNA viral load (&gt;600,000 or &gt;800,000 IU/mL), but found no difference in likelihood of SVR in patients with lower viral load.</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
### Table A. Summary of evidence on comparative effectiveness of treatment for hepatitis C (continued)

<table>
<thead>
<tr>
<th>Key Question 2b</th>
<th>Outcome</th>
<th>Summary of Evidence</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>How does the comparative effectiveness of antiviral treatment for intermediate outcomes vary according to patient subgroup characteristics? (continued)</td>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2a or Alfa-2b, Ribavirin, and Telaprevir vs. Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin</strong></td>
<td>One trial of response-guided triple therapy with telaprevir (12 weeks of pegylated interferon alfa-2a, ribavirin, and telaprevir followed by response-guided dual therapy with pegylated interferon alfa-2a and ribavirin) vs. dual therapy with pegylated interferon plus ribavirin for 48 weeks found no clear differences in relative risk estimates in patients stratified by age, sex, race, baseline fibrosis status, or body mass index. Characteristics associated with lower absolute rates of SVR were older age, Black race, advanced fibrosis or cirrhosis, and higher body mass index. One other trial of 24-week fixed duration triple therapy with telaprevir, pegylated interferon alfa-2b, and ribavirin vs. 48 weeks of dual therapy found no differences in estimates of effect in patients stratified by sex or age.</td>
<td>Moderate (for age and sex) Low (for other factors)</td>
</tr>
<tr>
<td></td>
<td>Sustained virologic response</td>
<td>Two trials of triple therapy with pegylated interferon (alfa-2a or alfa-2b), ribavirin, and telaprevir vs. dual therapy depending reported inconsistent findings for differential relative risk estimates according baseline viral load.</td>
<td>Insufficient</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Question 3a</th>
<th>Outcome</th>
<th>Summary of Evidence</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>What are the comparative harms associated with antiviral treatments?</td>
<td><strong>Dual Therapy With Pegylated Interferon Alfa-2b Plus Ribavirin vs. Dual Therapy With Pegylated Interferon Alfa-2a Plus Ribavirin</strong></td>
<td>Dual therapy with pegylated interferon alfa-2b was associated with slightly greater risk of headache (three trials, pooled RR 1.1, 95% CI 1.1 to 1.2; I²=0%), and a lower risk of serious adverse events (two trials, pooled RR 0.76; 95% CI 0.71 to 0.88; I²=0%), lower risk of neutropenia (five trials, pooled RR 0.61, 95% CI 0.46 to 0.83; I²=38%), and lower risk of rash (two trials, pooled RR 0.79, 95% CI 0.71 to 0.88; I²=0.0%) than dual therapy with pegylated interferon alfa-2a plus ribavirin, with no differences in withdrawals due to adverse events.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Harms</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Triple Therapy With Pegylated Interferon Alfa-2b, Ribavirin, and Boceprevir vs. Dual Therapy With Pegylated Interferon Alfa-2b Plus Ribavirin** | Harms | | Moderate |
| | Triple therapy with boceprevir for 48 weeks (pegylated interferon alfa-2b plus ribavirin for 4 weeks followed by addition of boceprevir for 44 weeks) was associated with increased risk of neutropenia (two trials, pooled RR 1.8, 95% CI 1.5 to 2.3; I²=0.0%), dysgeusia (two trials, pooled RR 2.5, 95% CI 2.0 to 3.2; I²=0.0%), anemia (two trials, pooled RR 2.0, 95% CI 1.4 to 2.8; I²=0.0%), and thrombocytopenia (two trials, pooled RR 3.2, 95% CI 1.2 to 8.2; I²=0.0%) than dual therapy with pegylated interferon alfa-2b plus ribavirin. The incidence of anemia was about 25% with triple therapy and the incidence of neutropenia about 33%, with severe anemia in 4–5% and severe neutropenia in 8–15%. | |
### Table A. Summary of evidence on comparative effectiveness of treatment for hepatitis C (continued)

<table>
<thead>
<tr>
<th>Key Question</th>
<th>Outcome</th>
<th>Summary of Evidence</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key Question 3a</strong>&lt;br&gt;What are the comparative harms associated with antiviral treatments? (continued)</td>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2a or Alfa-2b, Ribavirin, and Telaprevir vs. Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin</strong></td>
<td>Harms&lt;br&gt;In two trials, there were no statistically significant differences between a 12-week regimen of triple therapy with pegylated interferon alfa-2a, ribavirin, and telaprevir vs. dual therapy with pegylated interferon alfa-2a plus ribavirin in risk of any assessed adverse event.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Harms&lt;br&gt;In three trials, a 24-week regimen of triple therapy with telaprevir (pegylated interferon alfa-2a or alfa-2b, ribavirin, and telaprevir for 12 weeks followed by pegylated interferon alfa-2a plus ribavirin for 12 weeks) was associated with increased risk of anemia (three trials, pooled RR 1.3, 95% CI 1.1 to 1.5; I²=0.0%) and rash (three trials, pooled RR 1.4, 95% CI 1.1 to 1.7, I²=0.0%) vs. dual therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks. Among patients randomized to the 24-week telaprevir regimen, one to two-thirds experienced a rash (7–10% experienced severe rash) and 27–91% experienced anemia (4–11% experienced severe anemia). There was no difference in risk of withdrawal due to adverse events.</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Harms&lt;br&gt;In one trial, response-guided triple therapy with telaprevir (pegylated interferon alfa-2a, ribavirin, and telaprevir for 8 or 12 weeks followed by response-guided duration pegylated interferon alfa-2a and ribavirin) was associated with increased risk of withdrawal due to adverse events (27% vs. 7.2%, RR 3.8, 95% CI 2.6 to 5.7), anemia (38% vs. 19%, RR 2.0, 95% CI 1.6 to 2.5), any rash (36% vs. 24%, RR 1.5 , 95% CI 1.2 to 1.8), and severe rash (5% vs. 1%, RR 4.6, 95% CI 1.6 to 13) vs. therapy with pegylated interferon alfa-2a plus ribavirin for 48 weeks.</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td><strong>Key Question 3b</strong>&lt;br&gt;Do these harms differ according to patient subgroup characteristics?</td>
<td><strong>Dual Therapy With Pegylated Interferon Alfa-2b Plus Ribavirin vs. Dual Therapy With Pegylated Interferon Alfa-2a Plus Ribavirin</strong></td>
<td>Harms&lt;br&gt;No trial of dual therapy with pegylated interferon alfa-2b plus ribavirin vs. dual therapy with pegylated interferon alfa-2a plus ribavirin reported harms in patients stratified by factors such as HCV genotype, age, race, sex, stage of disease, or genetic markers. Three trials that restricted enrollment to patients with genotype 1 infection reported risk estimates for risk of harms that were similar to the risk estimates based on all trials.</td>
<td>Insufficient</td>
</tr>
<tr>
<td></td>
<td><strong>Triple Therapy With Pegylated Interferon Alfa-2a or Alfa-2b, Ribavirin, and Telaprevir or Boceprevir vs. Dual Therapy With Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin</strong></td>
<td>Harms&lt;br&gt;No trial evaluated harms associated with triple therapy with pegylated interferon, ribavirin, and boceprevir or telaprevir vs. dual therapy with pegylated interferon plus ribavirin in patient subgroups. All trials evaluated patients with genotype 1 infection.</td>
<td>Insufficient</td>
</tr>
</tbody>
</table>
systematic review, which found a shorter duration of treatment associated with a lower likelihood of achieving an SVR. The discrepancy may be explained by the inclusion in the other systematic review of a study that we excluded because it evaluated a nonstandard dose of pegylated interferon, as well as its inclusion of subgroup analyses from trials of patients randomized to different fixed durations of therapy prior to assessment of rapid virologic response, which we considered separately because they did not represent randomized comparisons of response-guided treatment.

Because telaprevir and boceprevir are so new, we are unaware of other published systematic reviews on the comparative benefits and harms of regimens including these drugs, compared with standard dual therapy. Our findings on the association between achieving an SVR and reduced risk of mortality or complications associated with chronic HCV infection are consistent with a recent review that used some systematic methods.

**Applicability**

The trials included in this review generally met criteria for efficacy studies based on the exclusion of patients with common comorbidities (such as serious psychiatric conditions or recent or ongoing substance abuse). In addition, the trials may have overestimated efficacy compared with what would be seen in typical practice due to improved adherence as a result of closer followup, effects of trial participation, selection of patients, or other factors. A separate review funded by AHRQ will be focusing on issues related to the screening for HCV infection in adults.

The severity of baseline liver disease in the patients enrolled in the trials suggests a broad range of patients were enrolled. In trials of triple therapy with boceprevir or telaprevir, the proportion of patients with cirrhosis at enrollment ranged from <1 to 11 percent.  Trials that reported the proportion of patients with minimal or no fibrosis reported rates of 27–39 percent.

<table>
<thead>
<tr>
<th>Key Question 4</th>
<th>Outcome</th>
<th>Summary of Evidence</th>
<th>Strength of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Have intermediate outcomes been shown to reduce the risk or rates of adverse health outcomes from HCV infection?</td>
<td>Mortality and long-term hepatic complications</td>
<td>A large VA hospital study that controlled well for potential confounders found an SVR after antiviral therapy associated with lower risk of all-cause mortality vs. no SVR (adjusted HR 0.71 [0.60-0.86], 0.62 [0.44-0.87] and 0.51 [0.35-0.75] for genotypes 1, 2, and 3, respectively). Eighteen other cohort studies found an SVR associated with decreased risk of all-cause mortality, liver-related mortality, HCC, and other complications of ESLD compared with no SVR, with stronger effect estimates than the VA study (adjusted HRs generally ranged from around 0.10 to 0.33). However, the studies had methodological shortcomings, including inadequate handling of confounders, and 10 were conducted in Asia.</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Short-term quality of life</td>
<td>Nine studies found an SVR associated with greater improvement in measures related to quality of life (generic or disease-specific) 24 weeks after the end of antiviral treatment vs. no SVR, with differences averaging less than 5 to 10 points on various SF-36 domains. All studies were poor-quality and were characterized by failure to adjust for confounders, high loss to followup, and failure to blind patients to SVR status.</td>
<td>Low</td>
</tr>
</tbody>
</table>

* bid = twice daily; CI = confidence interval; ESLD = end-stage liver disease; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HCV-RNA = hepatitis C virus ribonucleic acid; HR = hazard ratio; IU = international units; kg = kilograms; mcg = micrograms; mL = milliliters; RR = relative risk; SF-36 = Short Form (36) Health Survey; SVR = sustained virologic response; tid = three times daily; VA = U.S. Department of Veterans Affairs

"Current antiviral treatment regimen" refers to dual therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirin, or triple therapy with pegylated interferon (alfa-2a or alfa-2b) plus ribavirin and boceprevir or telaprevir.
Evidence to evaluate potential differences in comparative benefits or harms in patient subgroups based on age, sex, race, and other clinical factors was relatively limited, precluding strong conclusions in these specific subgroups. The strongest evidence on the association between an SVR versus no SVR after antiviral therapy and reduced mortality comes from a study performed in a VA population, which might limit generalizability to other settings. As described above, studies conducted in Asia on the association between an SVR after antiviral therapy and risk of clinical outcomes may be of limited applicability to U.S. populations because of a higher incidence of HCC in Asian patients with chronic HCV infection. However, the incidence of HCC is increasing in the United States in HCV-infected people, which may attenuate such concerns regarding applicability. The results of this CER are not applicable to populations excluded from the review, including patients previously treated with antiviral therapies and excluded populations such as patients with HIV coinfection, post-transplant patients, or hemodialysis patients. Antiviral therapy is not recommended in patients following kidney transplant, and ribavirin is not recommended in those with more severe (stage 3 to 5) kidney disease since it is renally cleared and associated with increased risk of hemolytic anemia in this setting. Such patients were typically excluded from randomized trials of antiviral treatment.

**Implications for Clinical and Policy Decisionmaking**

Our review has potential implications for clinical and policy decisionmaking. For patients with genotype 1 infection, triple therapy regimens with pegylated interferon alfa-2a or alfa-2b, ribavirin, and telaprevir or boceprevir may be considered an alternative to dual therapy with pegylated interferon alfa-2a or alfa-2b plus ribavirin as standard treatment due to substantially superior efficacy for achieving SVR compared with dual therapy with pegylated interferon alfa-2a or alfa-2b, as well as a shorter duration of treatment. Factors that may affect decisions to use regimens with boceprevir or telaprevir include cost and specific harms associated with use of these drugs (such as hematologic adverse events with boceprevir and anemia and rash with telaprevir). Dual therapy with pegylated interferon alfa-2a plus ribavirin appears to be associated with a higher likelihood of achieving SVR compared with dual therapy with pegylated interferon alfa-2b plus ribavirin, but absolute differences were relatively small. Therefore, decisions about which pegylated interferon to use may be affected by other considerations, such as cost, patient preferences, or other factors. For genotype 2 or 3 infection, standard doses and duration (24 weeks) of pegylated interferon as part of dual therapy are more effective than shorter regimens or lower doses, lending support to dosing guidance from the FDA and clinical practice guidelines. Evidence on differential effects of ribavirin dose are too limited to draw strong conclusions about optimal dosing of this component of antiviral regimens, although differences appeared relatively small.

The findings that absolute SVR rates are lower in certain subgroups (such as older patients, Black patients, patients with worse baseline fibrosis, and patients with high viral load) can be used to guide individualized decisionmaking. Patients who are less likely to achieve an SVR may make different informed decisions about therapy compared with those more likely to achieve an SVR, given the adverse effects associated with treatment.

The findings of the review are also relevant to screening recommendations, which are based in part on the effectiveness of treatments in people found through screening to have HCV infection. Important new evidence that may affect assessments regarding potential benefits of screening include stronger evidence on the link between achieving an SVR and improvement in clinical outcomes, as well as evidence showing substantially higher SVR rates with newer triple therapy regimens with boceprevir or telaprevir in patients with genotype 1 infection, the predominant type of HCV infection in the United States.

**Limitations of the Comparative Effectiveness Review Process**

Our review had some potential limitations. We excluded non–English-language articles, which could result in language bias, although a recent systematic review found little empirical evidence that exclusion of non–English-language articles leads to biased estimates for noncomplementary or alternative medicine interventions. We did not formally assess for publication bias with funnel plots due to small numbers (<10) of studies for all comparisons. Small numbers of studies can make interpretation of funnel plots unreliable, and experts suggest 10 studies as the minimum number of studies to perform them. We included some studies that were published only as abstracts and found their inclusion or exclusion from analyses did not change conclusions. In addition, we searched trial registries and solicited drug manufacturers for additional unpublished trials and identified none.
Another potential limitation is that we included cohort studies to evaluate the association between SVR and either mortality or hepatic complications associated with chronic HCV infection. Such studies are susceptible to confounding if factors associated with SVR (such as age, race, viral load, or fibrosis stage) are also associated with these outcomes. Therefore, we only included studies that reported adjusted risk estimates, and we evaluated how well studies addressed key potential confounders as part of our quality assessment. Nonetheless, residual confounding is a possibility, even in cohort studies that adjust for potential confounding.

**Limitations of the Evidence Base**

We identified several important limitations of the evidence base. First, studies assessing important long-term clinical outcomes associated with current antiviral treatments for chronic HCV infection are not available. In the case of antiviral regimens involving newly approved antiviral drugs, such studies are not possible yet because of the extended followup required to adequately evaluate effects on clinical outcomes. Second, no trials directly compared regimens with boceprevir with regimens with telaprevir. Given the increased efficacy of these regimens for genotype 1 infection, trials directly comparing their effects would be helpful for guiding health care providers’ treatment choices between these drugs. Third, few trials have evaluated the regimens approved specifically by the FDA for these drugs, limiting confidence in conclusions regarding estimates of benefits and harms for the regimens likely to be used in clinical practice. Fourth, few methodologically rigorous studies conducted in settings applicable to U.S. populations evaluated the association between achieving an SVR and improvements in clinical outcomes. Such studies would be very helpful for confirming the results of the recent large, well-conducted VA cohort study showing an association between achieving an SVR and reduced mortality risk.³³

**Future Research**

Evaluating the comparative effectiveness of current antiviral regimens on clinical outcomes in randomized trials or cohort studies is a challenge due to the long lead time and large sample sizes necessary to adequately assess these outcomes. This might be more feasible if the studies were to focus on populations at higher risk for complications from chronic HCV infection (e.g., patients with baseline cirrhosis, high viral load, or other risk factors for progression).

For all trials of antiviral treatments, studies that enroll broader populations with medical and psychological comorbidities, as frequently encountered in clinical practice, are needed to better understand comparative effectiveness, rather than just comparative efficacy. Studies designed using an effectiveness paradigm would also be helpful for understanding real-world outcomes of antiviral regimens, including effects related to the poorer treatment adherence than expected from efficacy trials. Trials directly comparing triple therapy with telaprevir compared with triple therapy with boceprevir would be very helpful for understanding comparative effectiveness of these two protease inhibitors. In addition, trials evaluating the boceprevir regimen recommended by the FDA in antiviral-naïve patients without baseline cirrhosis are needed to verify that results from studies of previously treated patients were appropriately generalized. Prolonged followup of patients exposed to telaprevir and boceprevir is needed to understand the long-term harms associated with these medications. A number of other protease inhibitors and other newer drugs for treatment of hepatitis C virus infection are currently in active development, and further studies with new drugs and drug regimens are expected, including regimens without interferon.³⁹

It is critical that future studies that evaluate clinical outcomes in patients with an SVR versus no SVR after antiviral therapy adequately control for other factors that influence clinical outcomes in chronic HCV infection. Studies on effects of achieving an SVR on long-term quality of life would be very helpful for understanding other potential clinical benefits of antiviral therapy, but a significant challenge is whether it is possible to ethically blind patients to virologic status, which may have an important effect on assessments of quality of life.

**References**


25. FDA. Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). 2011. www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm.


56. Marcellin P, Forns X, Goessler T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011 Feb;140(2):459-68.e1; quiz e14. PMID: 21034744.


**Full Report**


**For More Copies**

For more copies of Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness Review Executive Summary No. 76 (AHRQ Pub. No. 12(13)-EHC113-1), please call the AHRQ Publications Clearinghouse at 1-800-358-9295 or email ahrqpubs@ahrq.gov.